**COVERING LETTER**

"Upon acceptance by Asian Journal of Medical Sciences, all copyright ownership for the article is transferred to Asian Journal of Medical Sciences. We, the undersigned co-authors of this article, have contributed significantly to and share in the responsibility for above. The undersigned stipulate that the material submitted to Asian Journal of Medical Sciences is new, original and has not been submitted to another publication for concurrent consideration.


We also attest that any human and /or animal studies undertaken as part of the research from which this manuscript was derived are in compliance with regulation of our institution(s) and with generally accepted guidelines governing such work.

We further attest that we have herein disclosed any and all financial or other relationships which could be construed as a conflict of interest and that all sources of financial support for this study have been disclosed and are indicated in the acknowledgement. This statement must be signed by all the major co-authors."


 The manuscript has been seen and approved by all authors


Author's name Signature Date Place

**Name Signature Date signed**

1 Rajat Rana  April 16, 2014

2 Soumadip das  April 18, 2014

3 Aravinda Swami  April 18 2014

4 Sappa Dilip Kumar  April 21, 2014

5 S Ramesh C:\Users\Dr RAJ\Desktop\ramesh.gif April 25, 2014

6 Doreen Pon  April 20, 2014

To

The Editor

**Sub:** Submission of Manuscript for publication

Dear Sir,

We intend to publish an article entitled **“Strategic Therapeutic Approaches to Overcome Emerging Dual SRC/ABL kinase inhibitors Resistances in Chronic Phase Ph Positive Chronic Myeloid Leukemia”’** in your journal as an original Article.

On behalf of all the contributors I will act and guarantor and will correspond with the journal from this point onward.

Prior publication **NIL**

Support **NIL**

Conflicts of interest **NIL**

We also agree to provide post-publication update on the article.

Since drug therapy of chronic myeloid leukaemia is an ever evolving field, there is extensive need to update the knowledge. This study solves the ambiguity that existed over selection of drug therapy and emerging resistances as there is lack of published data on this issue. This study acknowledges various emerging concepts in rational drug designing and targeted therapy which are mainstay of contemporary clinical scenario. We are sure this topic will attract the attention of all health care professionals and also help your wide readerships.

We have done sufficient work in the field to justify authorship for this article.

**CONTRIBUTIONS OF AUTHORS**

**RR** designed the review; developed the protocol; identified selected, extracted and entered data; AS analyzed the data, wrote the first draft of the manuscript and updated the review.**SD** applied eligibility criteria, extracted data, reviewed the draft and final versions of the manuscript.**DK** critically appraised the studies to be included in the review, collaborated in the design of the review and the development of the protocol and double checked eligibility and quality, and **SL** reviewed the draft and final versions of the manuscript.

We hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the journal, in the event that such work is published by the journal.

Thanking you,

Yours’ sincerely,

**RAJAT RANA**



**Corresponding contributor: RAJAT RANA,** *R.M Medical College & Hospital, Annamalai University, India 608002,* E-mail - **rajatrana91@gmail.com**